Michal Lotem
YOU?
Author Swipe
View article: Impact of COVID-19 on cutaneous squamous cell carcinoma severity in a tertiary referral center in Israel: Lessons for future pandemics
Impact of COVID-19 on cutaneous squamous cell carcinoma severity in a tertiary referral center in Israel: Lessons for future pandemics Open
View article: RNA splicing dynamics in CD8 T cells uncovers isoforms that impact T cell-mediated cancer immunotherapy
RNA splicing dynamics in CD8 T cells uncovers isoforms that impact T cell-mediated cancer immunotherapy Open
Immune checkpoint blockade has transformed cancer therapy, yet many patients fail to respond, and few new targets have emerged beyond PD-1 and CTLA-4. Alternative splicing dramatically diversifies the T cell proteome, but the functional ro…
View article: Unveiling alternative splicing dynamics in activated T lymphocytes and their implications for immune checkpoint blockade efficacy
Unveiling alternative splicing dynamics in activated T lymphocytes and their implications for immune checkpoint blockade efficacy Open
Alternative splicing (AS) generates diverse mRNA transcripts from a single gene, enhancing protein variety. This study examines AS during naive CD4 T cell activation, revealing that splicing events precede gene expression changes, evident …
View article: Alternative splicing of modulatory immune receptors in T lymphocytes: a newly identified and targetable mechanism for anticancer immunotherapy
Alternative splicing of modulatory immune receptors in T lymphocytes: a newly identified and targetable mechanism for anticancer immunotherapy Open
Alternative splicing (AS) is a mechanism that generates translational diversity within a genome. Equally important is the dynamic adaptability of the splicing machinery, which can give preference to one isoform over others encoded by a sin…
View article: Immune organization in sentinel lymph nodes of melanoma patients is prognostic of distant metastases
Immune organization in sentinel lymph nodes of melanoma patients is prognostic of distant metastases Open
Sentinel lymph node (sLN) biopsy is part of melanoma staging, as involved LNs indicate a higher risk of recurrence. However, how the sLN is shaped by the tumor and reciprocally affects metastatic progression is poorly understood. Here, we …
View article: Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events
Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events Open
Given the broad implementation of immune checkpoint inhibitors (ICI) for cancer therapy, we encounter a variety of immune-related adverse events (irAE) including immune-related blood eosinophilia. Eosinophilia demonstrated a potential posi…
View article: Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer
Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer Open
PURPOSE Current guidelines for the management of metastatic non–small cell lung cancer (NSCLC) without driver mutations recommend checkpoint immunotherapy with PD-1/PD-L1 inhibitors, either alone or in combination with chemotherapy. This a…
View article: Interferon-stimulated neutrophils as a predictor of immunotherapy response
Interferon-stimulated neutrophils as a predictor of immunotherapy response Open
Despite the remarkable success of anti-cancer immunotherapy, its effectiveness remains confined to a subset of patients-emphasizing the importance of predictive biomarkers in clinical decision-making and further mechanistic understanding o…
View article: 1229 Pre-treatment plasma proteomics-based predictive biomarkers for immune related adverse events in non-small cell lung cancer
1229 Pre-treatment plasma proteomics-based predictive biomarkers for immune related adverse events in non-small cell lung cancer Open
Background Immune-related adverse events (irAEs) resulting from immune checkpoint inhibitors (ICIs) can substantially affect patient quality of life and treatment trajectory. Currently, there are no reliable pre-treatment biomarkers for pr…
View article: <scp>Tumor‐infiltrating</scp> lymphocyte transfusion in a patient with treatment refractory triple negative breast cancer
<span>Tumor‐infiltrating</span> lymphocyte transfusion in a patient with treatment refractory triple negative breast cancer Open
Background Triple negative breast cancer (TNBC) is an aggressive form of breast cancer that is treated with chemotherapy. Recently, programmed death 1 (PD1) inhibition, as well as antibody‐drug conjugates, have been added to the available …
View article: The future of affordable cancer immunotherapy
The future of affordable cancer immunotherapy Open
The treatment of cancer was revolutionized within the last two decades by utilizing the mechanism of the immune system against malignant tissue in so-called cancer immunotherapy. Two main developments boosted cancer immunotherapy: 1) the u…
View article: Data from Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions
Data from Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions Open
SLAMF6 is a homotypic receptor of the Ig-superfamily associated with progenitor-exhausted T cells. Here we show that in humans, SLAMF6 has three splice isoforms involving its V-domain. Although the canonical receptor inhibited T-cell activ…
View article: Supplementary Figures S1-5 from Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions
Supplementary Figures S1-5 from Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions Open
Supplementary Figures S1-5
View article: Data from Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions
Data from Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions Open
SLAMF6 is a homotypic receptor of the Ig-superfamily associated with progenitor-exhausted T cells. Here we show that in humans, SLAMF6 has three splice isoforms involving its V-domain. Although the canonical receptor inhibited T-cell activ…
View article: Supplementary Figures S1-5 from Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions
Supplementary Figures S1-5 from Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions Open
Supplementary Figures S1-5
View article: Data from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma
Data from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma Open
The quest for tumor-associated antigens (TAA) and neoantigens is a major focus of cancer immunotherapy. Here, we combine a neoantigen prediction pipeline and human leukocyte antigen (HLA) peptidomics to identify TAAs and neoantigens in 16 …
View article: Supplementary Tables 3, 6, 7, 9, 11, 12 from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma
Supplementary Tables 3, 6, 7, 9, 11, 12 from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma Open
Supplementary Tables 3, 6, 7, 9, 11, 12
View article: Supplementary Movies 1-3 from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma
Supplementary Movies 1-3 from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma Open
In vitro killing assay movies. Co-culture of 12T melanoma cells with autologous 12TILs
View article: Supplementary Movies 4-6 from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma
Supplementary Movies 4-6 from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma Open
In vitro killing assay movies. Co-culture of 12T melanoma cells with irrelevant 108TILs
View article: Data from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma
Data from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma Open
The quest for tumor-associated antigens (TAA) and neoantigens is a major focus of cancer immunotherapy. Here, we combine a neoantigen prediction pipeline and human leukocyte antigen (HLA) peptidomics to identify TAAs and neoantigens in 16 …
View article: Supplementary Tables 1, 2, 4, 5, 8, 10, 13, 14, 15 from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma
Supplementary Tables 1, 2, 4, 5, 8, 10, 13, 14, 15 from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma Open
Supplementary Tables 1, 2, 4, 5, 8, 10, 13, 14, 15
View article: Supplementary Figures 1-17 from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma
Supplementary Figures 1-17 from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma Open
Supplementary Figures 1-17
View article: Figure S4 from Soluble SLAMF6 Receptor Induces Strong CD8<sup>+</sup> T-cell Effector Function and Improves Anti-Melanoma Activity <i>In Vivo</i>
Figure S4 from Soluble SLAMF6 Receptor Induces Strong CD8<sup>+</sup> T-cell Effector Function and Improves Anti-Melanoma Activity <i>In Vivo</i> Open
The addition of seSLAMF6 to IL-2 has no synergistic effect on cytotoxicity
View article: Figure S3 from Soluble SLAMF6 Receptor Induces Strong CD8<sup>+</sup> T-cell Effector Function and Improves Anti-Melanoma Activity <i>In Vivo</i>
Figure S3 from Soluble SLAMF6 Receptor Induces Strong CD8<sup>+</sup> T-cell Effector Function and Improves Anti-Melanoma Activity <i>In Vivo</i> Open
Anti-SLAMF6 antibody had no direct effect on T cell activation
View article: Figure S1 from Soluble SLAMF6 Receptor Induces Strong CD8<sup>+</sup> T-cell Effector Function and Improves Anti-Melanoma Activity <i>In Vivo</i>
Figure S1 from Soluble SLAMF6 Receptor Induces Strong CD8<sup>+</sup> T-cell Effector Function and Improves Anti-Melanoma Activity <i>In Vivo</i> Open
SLAMF6 expression on human lymphocytes
View article: Table S1 from Soluble SLAMF6 Receptor Induces Strong CD8<sup>+</sup> T-cell Effector Function and Improves Anti-Melanoma Activity <i>In Vivo</i>
Table S1 from Soluble SLAMF6 Receptor Induces Strong CD8<sup>+</sup> T-cell Effector Function and Improves Anti-Melanoma Activity <i>In Vivo</i> Open
Tumor infiltrating lymphocytes used in the study
View article: Supplementary Movies 7-9 from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma
Supplementary Movies 7-9 from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma Open
2P microscopy movies of in vivo experiments
View article: Figure S2 from Soluble SLAMF6 Receptor Induces Strong CD8<sup>+</sup> T-cell Effector Function and Improves Anti-Melanoma Activity <i>In Vivo</i>
Figure S2 from Soluble SLAMF6 Receptor Induces Strong CD8<sup>+</sup> T-cell Effector Function and Improves Anti-Melanoma Activity <i>In Vivo</i> Open
SLAMF6 Overlapping-peptide SPOT array showing seSLAMF6 binding sequences
View article: Figure S2 from Soluble SLAMF6 Receptor Induces Strong CD8<sup>+</sup> T-cell Effector Function and Improves Anti-Melanoma Activity <i>In Vivo</i>
Figure S2 from Soluble SLAMF6 Receptor Induces Strong CD8<sup>+</sup> T-cell Effector Function and Improves Anti-Melanoma Activity <i>In Vivo</i> Open
SLAMF6 Overlapping-peptide SPOT array showing seSLAMF6 binding sequences
View article: Supplementary methods from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma
Supplementary methods from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma Open
Supplementary methods